← 返回

超声特征联合 TIL(肿瘤浸润淋巴细胞)预测乳腺癌新辅助化疗的病理反应

英文原题:Ultrasound features combined with tumor-infiltrating lymphocytes for prediction of pathological response to neoadjuvant chemotherapy in breast cancer.

查看英文原题

Ultrasound features combined with tumor-infiltrating lymphocytes for prediction of pathological response to neoadjuvant chemotherapy in breast cancer.

PubMed 2023/06/26(内容时间) Med Ultrason Q2 · IF 1.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

该模型结合了 US 特征、临床特征和 TIL 水平,在预测乳腺癌对 NAC 的病理反应方面表现更好。

研究思路结论见上方概要

新辅助化疗(NAC)在乳腺癌的治疗和预后中发挥着重要作用。早期识别真正能够从前瞻性NAC中获益的患者在临床实践中至关重要。本研究的目的是探讨超声特征和临床特征联合TIL(肿瘤浸润淋巴细胞)水平是否能提高预测乳腺癌患者NAC疗效的性能。

在这项回顾性研究中,纳入了202例接受NAC后手术的浸润性乳腺癌患者。由两名放射科医师回顾基线超声特征。采用Miller-Payne Grading(MPG)评估病理反应,MPG 4-5定义为主要组织学缓解者(MHR)。采用多变量logistic回归分析评估MHR的独立预测因素并构建预测模型。采用受试者工作特征(ROC)曲线评估模型的性能。

在202例患者中,104例达到MHR,98例未达到MHR。多因素logistic回归分析显示,US大小(p=0.042)、分子亚型(p=0.001)、TIL水平(p<0.001)、形状(p=0.030)和后部特征(p=0.018)是MHR的独立预测因素。结合US特征、临床特征和TIL水平的模型表现更优,曲线下面积(AUC)为0.811,敏感性为0.663,特异性为0.847。

展开英文摘要原文

Of the 202 patients, 104 patients achieved MHR and 98 patients achieved non-MHR. Multivariate logistic regression analysis showed the US size (p=0.042), molecular subtypes (p=0.001), TIL levels (p<0.001), shape (p=0.030), and posterior features (p=0.018) were independent predictors for MHR. The model combined the US features, clinical characteristics, and TIL levels had a better performance with an area under the curve (AUC) of 0.811, a sensitivity of 0.663, and a specificity of 0.847.

The model combined US features, clinical characteristics, and TIL levels had a better performance in predicting pathological response to NAC in breast cancer.

论文信息

作者
Jia Y、Zhou X、Zhu Y、Song X、Duan Y、Chen K、Nie F
第一作者单位
Ultrasound Medical Center, Lanzhou University Second Hospital, Lanzhou, Gansu, China. 674349577@qq.com.China
通讯作者单位
Ultrasound Medical Center, Lanzhou University Second Hospital, China. ery_nief@lzu.edu.cn.China
期刊
Medical ultrasonography2023 Jun 26
原文标识
PubMed 37369044 · DOI 10.11152/mu-3909